Gatifloxacin + DexamethasoneThird Party Manufacturing in India

Gatifloxacin + Dexamethasone works by simultaneously halting bacterial replication and suppressing the cellular inflammatory response. It inhibits bacterial DNA gyrase and topoisomerase IV to induce lethal DNA fragmentation, while binding to nuclear glucocorticoid receptors to block the transcription of pro-inflammatory cytokines. Unlike simple antibiotic single-agent formulations, it addresses both the root infectious cause and the symptomatic tissue swelling at the same time. It is highly effective and well-tolerated under controlled clinical monitoring.

Therapeutic Uses

• Steroid-Responsive Ocular Infections: Management of bacterial conjunctivitis and keratitis where structural anti-inflammatory action is required.
• Post-Surgical Prophylaxis: Prevention of infection and control of post-cataract ocular swelling.

Why Manufacturers Choose Gatifloxacin + Dexamethasone

Gatifloxacin + Dexamethasone third party manufacturing in India remains an important segment within the domestic healthcare trade due to high clinical preference for fixed-dose combinations. Our partner manufacturing sites use high-precision aseptic fill-finish processes that strictly follow WHO-GMP protocols to prevent cross-contamination and ensure exact ingredient distribution. This clear alignment with WHO-GMP standards satisfies critical hospital quality protocols and facilitates faster entry into international export markets. Offering this trusted pair strengthens any commercial ophthalmic catalogue.